ALK and non-small cell lung carcinoma: Targeted agents such as erlotinib or gefitinib (EGFR inhibitor) or crizotinib or ceritinib (ALK inhibitors) have shown activity in NSCLC (non-small cell lung cancer) which possess these putative types of mutation.